ACAD · NASDAQ · STOCK
ACADIA Pharmaceuticals (ACAD) Stock Analysis
$19.64
52W $18.39 – $30.96
63/100
$3.19B
8.3
0.89
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is ACAD Bullish or Bearish?
Bullish.
Innellis AI committee rates ACADIA Pharmaceuticals Inc. (ACAD) Buy with a composite score of 63/100
, based on 6 analysts with 67% agreement.
Last updated October 14, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +11.86 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -8.14 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 47.0% yoy -- genuine top-line momentum. Technical Analyst remains cautious — price structure making lower highs and lower lows. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- P/E of 8.5 is inexpensive for the broad market — Value
- ROE of 32.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
- EPS growing 96.5% YoY — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
Bear Case
- Price structure making lower highs and lower lows — Technical
- RSI at 11 is in oversold territory (could mean either capitulation or a bounce setup) — Technical
- MACD histogram negative -- bearish momentum — Technical
- Price structure (HH_HL) contradicts the downtrend -- mixed signals — Technical
- Daily trend (downtrend) conflicts with the weekly trend (uptrend) -- fighting the larger trend — Technical
- Weekly RSI at 21 -- oversold on the larger timeframe too — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 14, 2026
Overall Committee Score
63/100
Agreement
67%
Analysts
6
Conviction
Contested
Sector Rank
Top 14%
of 192 Healthcare peers
Value Analyst
bullish
70
/ 100 · High confidence
Classic value case: cheap on multiples with earnings power to back it up
+ P/E of 8.5 is inexpensive for the broad market
Growth Analyst
bullish
85
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 47.0% YoY -- genuine top-line momentum
Technical Analyst
bearish
33
/ 100 · High confidence
Price action is deteriorating -- trend and/or momentum are working against this name
− Price structure making lower highs and lower lows
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 59.0% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
68
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.33 across 6 articles, 14d)
Portfolio Manager
bearish
35
/ 100 · Low confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− 2 existing position pair(s) are highly correlated already
Investment Thesis Evolution
Committee score moved marginally from 66.1 to 63.1.
- New bearish signals: 6 appeared.
- Bullish support removed: 3 signal(s) disappeared.
- New bullish signals: 2 appeared.
- Bearish pressure eased: 4 signal(s) disappeared.
Analyst-level changes:
- Macro Analyst: score 80->65 (-15).
- News Analyst: +1 bullish signal(s).
- Portfolio Manager: score 30->35 (+5).
- Risk Analyst: +1 bearish signal(s).
- Technical Analyst: score 38->33 (-5); +5 bearish signal(s).
- Value Analyst: +1 bullish signal(s).
Comparing 2026-10-13 to 2026-10-14 (1 day apart).
Technical Analysis
RSI (14)
28.3
Oversold
MACD Histogram
-0.023
Bearish Momentum
Trend Direction
Downtrend
Weekly: Uptrend
Market Structure
Hh Hl
Support
$13.40
Resistance
$23.07
Bollinger %B
0.30
Inside Bands
Price vs Moving Averages
EMA 9
$19.74
Below
EMA 21
$21.59
Below
EMA 50
$23.88
Below
EMA 200
$24.10
Below
Fundamental Analysis
Valuation
95
Growth
72
Profitability
100
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
8.3×
P/B Ratio
2.45×
PEG Ratio
0.12
Dividend Yield
0.00%
52W High
$30.96
52W Low
$18.39
Quality & Growth
ROE
3185.6%
ROA
2499.7%
Gross Margin
9113.2%
Operating Margin
758.5%
Revenue Growth YoY
—
Debt / Equity
0.06
AI Fundamental Assessment
P/E ratio of 8.3 (inexpensive relative to a 15-40x range); Price-to-book of 2.4x; PEG ratio of 0.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 31.9%; Return on assets of 25.0%; Net margin of 33.4%; Gross margin of 91.1%; Current ratio of 3.39 (healthy short-term liquidity); Debt-to-equity of 0.06; Free cash flow per share is positive (1.02); Most recent quarter beat estimates by 207.2%; EPS growth accelerating (-98.8% -> +800.0% QoQ); Analyst estimates falling over recent quarters
Get the Full ACAD Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →